#AskDrDurie

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

May
01
Proteasome Inhibitors in Multiple Myeloma
The following are excerpts from the IMF and Medscape Education Oncology CME activity Ask Dr. Durie - Doctors' Edition: Proteasome Inhibitors in Multiple Myeloma.Now available from Medscape are CME(...)
Apr
26
What does it mean for myeloma patients if their Freelite test results show antigen-excess?
In this week’s video, Dr. Brian G.M. Durie explains why a Freelite test may be inaccurate. The BOTTOM LINE: Discuss abnormal Freelite test results with your doctor, and if necessary, test further by(...)
Apr
19
When should a myeloma patient begin treatment?
In this week’s video, Dr. Brian G.M. Durie explains which criteria and tests determine if a patient’s myeloma is smoldering or active.
Apr
12
Should myeloma patients stay on maintenance therapy for several years?
In this week’s video, Dr. Brian G.M. Durie explains that maintenance therapy can prolong remissions and delay relapse. BOTTOM LINE: ​ The BOTTOM LINE: If maintenance therapy is well-tolerated, stick(...)
Apr
05
Options for myeloma patients who have undergone Darzalex (daratumumab) therapy and relapsed
In this week’s video, Dr. Brian G.M. Durie explains that if you relapse on Darzalex, it is important to carefully discuss all treatment options with your doctor.
Mar
29
Should myeloma patients undergo genetic testing to determine their best treatment options?
In this week’s video, Dr. Brian G.M. Durie explains why genetic sequencing tests are not yet precise enough to use for choosing myeloma therapies.